Hilary McElwaine-Johnn
Corporate Officer/Principal chez The Royal College of Physicians
Profil
Hilary McElwaine-Johnn is a professional with experience in various firms.
She is currently a Member at The Royal College of Physicians.
She has previously worked as a Medical Director at Seqirus Vaccines Ltd., an Associate Medical Director at Powderject Pharmaceuticals Plc, a Principal at PowderMed Ltd., a Chief Marketing Officer at Vantia Ltd., a Chief Medical Officer at Akamis Bio Ltd., and a Chief Medical Officer at EXACT Therapeutics AS.
Dr. McElwaine-Johnn completed her undergraduate degree at Imperial College London.
Postes actifs de Hilary McElwaine-Johnn
| Sociétés | Poste | Début |
|---|---|---|
| The Royal College of Physicians | Corporate Officer/Principal | 24/11/2009 |
Anciens postes connus de Hilary McElwaine-Johnn
| Sociétés | Poste | Fin |
|---|---|---|
| EXACT THERAPEUTICS | Chief Tech/Sci/R&D Officer | - |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Seqirus Vaccines Ltd.
 Seqirus Vaccines Ltd. BiotechnologyHealth Technology Seqirus Vaccines Ltd. manufactures vaccines. The company is headquartered in Maidenhead, the United Kingdom. | Corporate Officer/Principal | - |
Powderject Pharmaceuticals Plc
 Powderject Pharmaceuticals Plc Medical SpecialtiesHealth Technology Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK | Corporate Officer/Principal | - |
PowderMed Ltd.
 PowderMed Ltd. Pharmaceuticals: MajorHealth Technology PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom. | Corporate Officer/Principal | - |
Formation de Hilary McElwaine-Johnn
| Imperial College London | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EXACT THERAPEUTICS | Health Technology |
| Entreprise privées | 5 |
|---|---|
Seqirus Vaccines Ltd.
Seqirus Vaccines Ltd. BiotechnologyHealth Technology Seqirus Vaccines Ltd. manufactures vaccines. The company is headquartered in Maidenhead, the United Kingdom. | Health Technology |
Powderject Pharmaceuticals Plc
Powderject Pharmaceuticals Plc Medical SpecialtiesHealth Technology Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK | Health Technology |
PowderMed Ltd.
PowderMed Ltd. Pharmaceuticals: MajorHealth Technology PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom. | Health Technology |
Vantia Ltd.
 Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Commercial Services |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
